Back to Index
Araz Marachelian, MD
Assistant Professor of Clinical Pediatrics
CHL Mail Stop 54 Off Campus Los Angeles
+1 323 361 8573


Undergraduate Research Award National Science Foundation

University of California, Berkeley: Outstanding Service Award, 1995

University of California, Berkeley: High Distinction of Honors, 1995

University of California, Irvine: Outstanding Achievement in Pediatrics and Psychiatry, 1999

AACR/ASCO: Clinical Trial Training Workshop Award, 2005

Southern California Super Doctors

Pasadena Magazine: Top Doctor, 2013

Southern California Super Doctors

NCI Cancer Clinical Investigator Team Leadership Award (CCITLA)


Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016 Oct; 66:144-52. View in: PubMed

Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 Aug; 63(8):1349-56. View in: PubMed

Jackson JR, Tran HC, Stein JE, Shimada H, Patel AM, Marachelian A, Kim ES. The clinical management and outcomes of cervical neuroblastic tumors. J Surg Res. 2016 Jul; 204(1):109-13. View in: PubMed

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75. View in: PubMed

Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With (131) I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42. View in: PubMed

Marachelian A, Desai A, Balis F, Katzenstein H, Qayed M, Armstrong M, Neville KA, Cohn SL, Bush M, Gunawan R, Lim AP, Smith MA, Mary Smith L. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14. 18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12. View in: PubMed

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. View in: PubMed

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. (131)I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. View in: PubMed

Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31. View in: PubMed

Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes. 2014; 7(1):256. View in: PubMed

Brown RJ, Rahim H, Wong KE, Cooper RM, Marachelian A, Butturini A, Dhall G, Finlay JL. Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors. Pediatr Blood Cancer. 2013 Dec; 60(12):2012-7. View in: PubMed

Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. View in: PubMed

Giuliani S, Marachelian A, Franklin A, Shimada H, Grikscheit T. Forearm skeletal muscle neuroblastoma in a child: a rare primary location. J Pediatr Hematol Oncol. 2013 Jan; 35(1):61-3. View in: PubMed

Marachelian A, Shimada H, Sano H, Jackson H, Stein J, Sposto R, Matthay KK, Baker D, Villablanca JG. The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatr Blood Cancer. 2012 May; 58(5):675-81. View in: PubMed

DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 1; 18(9):2679-86. View in: PubMed

Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. View in: PubMed

Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer. 2010 Jul 15; 55(1):42-6. View in: PubMed

Bavishi S, Wong K, Delgardo T, Marachelian A, Khatua S. Successful radiation therapy for supratentorial primitive neuroectodermal tumor and epidermolysis bullosa simplex. Pediatr Blood Cancer. 2010 Jan; 54(1):170-2. View in: PubMed

Butturini AM, Jacob M, Aguajo J, Vander-Walde NA, Villablanca J, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Finlay JL. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome. Cancer. 2009 Jul 1; 115(13):2956-63. View in: PubMed

Marachelian A, Butturini A, Finlay J. Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transplant. 2008 Jan; 41(2):167-72. View in: PubMed

Jubran RF, Marachelian A, Dorey F, Malogolowkin M. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Jul; 45(1):37-42. View in: PubMed

Powered bySC CTSI